Phreesia, Inc.: Series D $16M

Posted in I - Series D, Q - 2Q10, R - NORTH EAST, X - Bioinformatics, X - TeleMedicine, XX - NY

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

Rheonix, Inc.: Series A $12.6M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Device (Diagnostic), XX - NY

Rheonix (Ithaca, NY) a development-stage molecular diagnostic company focused on immunoassays, pathogen identification gene sequence detection and cell-based assays, closed a $12.6M Series A financing. Participants include Cayuga Venture Fund.

Aureon Laboratories, Series D: $7M

Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, X - PSA, XX - NY

Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.

Intercept Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - Cirrhosis, X - Diabetes, X - FXR, XX - NY

Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.

Therasis, Inc.: Series A $12M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Computational Discovery, X - Device (HTS), XX - NY

Therasis (New York, NY) a development-stage computational systems biology cancer HTS drug discovery platform, closed a $12M Series A financing. Participants include Tilocor Life Science.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Curemark, Inc.: Series A $6.5M

Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - ADHD, X - CNS, XX - NY

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Paradigm Spine, LLC: Series E $6.5M

Posted in I - Series E, Q - 3Q09, R - NORTH EAST, X - Device (Spine), XX - NY

Paradigm Spine (New York, NY) a clinical-stage medical device company focused on lumbar stabilization and interspinous implants, closed a $6.5M Series E financing. Participants include Praefinium Group and Trevi Health Ventures.

Core Dynamics, Inc.: Series B $17.9M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Sample Storage, XX - NY

Core Dynamics (Orangeburg, NY) a development-stage company focused on the freezing and lyophilization of white blood cells and stem cells and their preservation and storage at room temperature, closed a $17.9M Series B financing. Participants were not disclosed.

MetaCure, Inc.: Series B $20M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Device (Diabetes), XX - NY

MetaCure (Orangeburg, NY) a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation, closed a $20M Series B financing. Participants include the Morningside Group.

Palyon Medical Corp.: Series A $21M

Posted in I - Series A, Q - 2Q09, R - NORTH EAST, X - Device (Delivery), XX - NY

Palyon Medical (New York, NY) a preclinical-stage medical device company focused on a spin-based drug delivery system, closed a $21M Series A financing. Participants include Baird Venture Partners, Hambrecht & Quist, Fountain Healthcare Partners, BB Biotech Ventures, Cross Atlantic Partners and Arcus Ventures.

« Previous Entries

to top of page...